Dong-A Makes It Five: Accord Gears Up For US Launch After Ustekinumab Approval
Settlement Date Provides Certainty Of Launch; Amgen’s US Launch Only Months Away
Partners Dong-A ST and Meiji Seika Pharma have demonstrated their credentials in the US biosimilar market, bagging a US Food and Drug Administration approval for their biosimilar Stelara product that will be commercialized by Accord Healthcare.
